DERIVE PEPTIDIQUE DE THIO-UREE, COMPOSE MARQUE PAR UN RADIO-ISOTOPE LE CONTENANT ET COMPOSITION PHARMACEUTIQUE LE CONTENANT EN TANT QUE PRINCIPE ACTIF POUR LE TRAITEMENT OU LE DIAGNOSTIC DU CANCER DE LA PROSTATE
The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound containing the same, and a pharmaceutical composition containing the same as an active ingredient for treating and diagnosing prostate cancer. The peptide thiourea derivative according to the present invention, when administered into the body, has excellent stability in the human serum, favorably binds to PSMA which is competitively expressed in prostate cancer, exhibits an excellent PSMA inhibitory effect with a low concentration, and can obtain a clear image of a prostate cancer tumor site by being excreted into the kidney rather than the hepatobiliary route due to high water solubility thereof. Therefore, the peptide thiourea derivative according to the present invention can be favorably used as a pharmaceutical composition for treating or diagnosing prostate cancer.
